Stock 2160 GNI GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights GNI Group Ltd.

Equities

2160

JP3386370005

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
2,325 JPY -2.11% Intraday chart for GNI Group Ltd. -0.04% -17.84%
05-31 Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy MT
03-19 Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy
MT
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024
CI
GNI Group Revises Fiscal 2023 Forecast Upwards after Subsidiaries Show Better-than-Expected Sales, Foreign Exchange Rates
MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2023
CI
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business
MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms
DJ
Elutia Sells Orthobiologics Business Unit For Up to $35 Million
MT
GNI Subsidiary Cullgen Closes Series C Funding
MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2023
CI
GNI Completes Investment in Shanghai JIUCE for China Expansion
MT
GNI Group Unit, Astellas Pharma Partner to Discover Innovative Protein Degraders
MT
GNI Group Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2023
CI
Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China
CI
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2023
CI
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2022
CI
GNI to Take Controlling Stake in Nasdaq-listed Catalyst Biosciences via Liver Fibrosis Drug Development Deals; Shares Up 3%
MT
Catalyst Biosciences Acquires F351, Controlling Interest in Continent From GNI Group
MT
GNI Group Ltd. and Catalyst Biosciences, Inc. Sign Agreements to Advance Liver Fibrosis Drug Development
CI
Catalyst Biosciences, Inc. Signed Agreements to acquire 65.2% stake in Catalyst Biosciences, Inc. from GNI Group Ltd. and Shanghai Genomics, Inc. for approximately CNY 3.8 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2160 Stock
  4. News GNI Group Ltd.
  5. Highlights